Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers-general business based in the US. It opened the day at $60.51 after a previous close of $61.23. During the day the price has varied from a low of $60.36 to a high of $61.415. The latest price was $61.31 (25 minute delay). Bristol-Myers Squibb is listed on the NYSE and employs 30,250 staff. All prices are listed in US Dollars.
How to buy shares in Bristol-Myers Squibb
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: BMY in this case.
- Research Bristol-Myers Squibb shares. The platform should provide the latest information available.
- Buy your Bristol-Myers Squibb shares. It's that simple.
Range of stock exchanges
What's in this guide?
- Can I buy shares in Bristol-Myers Squibb?
- Has coronavirus impacted Bristol-Myers Squibb shares?
- Bristol-Myers Squibb shares summary
- Compare share dealing platforms
- Is Bristol-Myers Squibb stock a buy or sell?
- Performance over time
- Can I short Bristol-Myers Squibb shares?
- Is Bristol-Myers Squibb suitable for ethical investing?
- Are Bristol-Myers Squibb shares over-valued?
- How volatile are Bristol-Myers Squibb shares?
- Does Bristol-Myers Squibb pay a dividend?
- Have Bristol-Myers Squibb shares ever split?
- Other common questions
How has coronavirus impacted Bristol-Myers Squibb's share price?
Since the stock market crash that started in February 2020, Bristol-Myers Squibb's share price has had significant negative movement.
Its last market close was $61.31, which is 6.58% down on its pre-crash value of $65.63 and 33.98% up on the lowest point reached during the March 2020 crash when the shares fell as low as $45.76.
If you had bought $1,000 worth of Bristol-Myers Squibb shares at the start of February 2020, those shares would have been worth $729.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $964.41.
Bristol-Myers Squibb share price (NYSE:BMY)Use our graph to track the performance of BMY stocks over time.
Bristol-Myers Squibb shares at a glance
|52-week range||$55.1871 - $69.75|
|50-day moving average||$66.6574|
|200-day moving average||$65.3036|
|Wall St. target price||$80.24|
|Dividend yield||$1.92 (3.14%)|
|Earnings per share (TTM)||$-2.264|
Fees for buying 10x Bristol-Myers Squibb shares with popular platforms
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
|Platform||Platform fee||Min. initial deposit||Trading fee estimate|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|£9.99 per month||No minimum||£14.74
|Capital at risk|
|Capital at risk|
|£36 per year||£20||£15.13
|Capital at risk|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Bristol-Myers Squibb stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Bristol-Myers Squibb price performance over time
|1 week (2021-09-13)||-2.43%|
|1 month (2021-08-20)||-11.40%|
|3 months (2021-06-18)||-7.76%|
|6 months (2021-03-19)||-2.22%|
|1 year (2020-09-18)||3.44%|
|2 years (2019-09-20)||21.24%|
|3 years (2018-09-20)||-0.71%|
|5 years (2016-09-20)||10.35%|
Is Bristol-Myers Squibb under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Bristol-Myers Squibb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 14.5784. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bristol-Myers Squibb's PEG ratio in relation to those of similar companies.
Bristol-Myers Squibb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $18.8 billion (£13.8 billion).
The EBITDA is a measure of a Bristol-Myers Squibb's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
|Revenue TTM||$44.4 billion|
|Operating margin TTM||18.55%|
|Gross profit TTM||$34 billion|
|Return on assets TTM||4.31%|
|Return on equity TTM||-11.76%|
|Market capitalisation||$136.2 billion|
TTM: trailing 12 months
How to short and sell Bristol-Myers Squibb shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "BMY.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 20.3 million Bristol-Myers Squibb shares held short by investors – that's known as the "short interest". This figure is 7.2% down from 21.9 million last month.
There are a few different ways that this level of interest in shorting Bristol-Myers Squibb shares can be evaluated.
Short interest ratio (SIR)
Bristol-Myers Squibb's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb shares currently shorted divided by the average quantity of Bristol-Myers Squibb shares traded daily (recently around 6.9 million). Bristol-Myers Squibb's SIR currently stands at 2.94. In other words for every 100,000 Bristol-Myers Squibb shares traded daily on the market, roughly 2940 shares are currently held short.
To gain some more context, you can compare Bristol-Myers Squibb's short interest ratio against those of similar companies.
However Bristol-Myers Squibb's short interest can also be evaluated against the total number of Bristol-Myers Squibb shares, or, against the total number of tradable Bristol-Myers Squibb shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb shares in existence, roughly 10 shares are currently held short) or 0.0093% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb.
Find out more about how you can short Bristol-Myers Squibb stock.
Environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb.
Total ESG risk score
Bristol-Myers Squibb's total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Bristol-Myers Squibb's total ESG risk score against those of similar companies.
- AstraZeneca (AZN.LSE): 28.52
- AbbVie (ABBV.US): 34.86
- Pfizer (PFE.US): 33.15
- Edwards Lifesciences Corporation (EW.US): 21.68
Bristol-Myers Squibb's environmental score: 3.83/100
Bristol-Myers Squibb's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb's social score: 18.82/100
Bristol-Myers Squibb's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb's governance score: 14.02/100
Bristol-Myers Squibb's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb's controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Bristol-Myers Squibb scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb has, for the most part, managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.16|
|Total ESG percentile||52.58|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Bristol-Myers Squibb share dividends
Dividend yield: 3.14% of stock value
Forward annual dividend yield: 3.2% of stock value
Dividend payout ratio: 28.99% of net profits
Bristol-Myers Squibb has recently paid out dividends equivalent to 3.14% of its share value annually.
Bristol-Myers Squibb has paid out, on average, around 28.99% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 3.2% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb's case, that would currently equate to about $1.92 per share.
While Bristol-Myers Squibb's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb's most recent dividend payout was on 31 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Bristol-Myers Squibb's dividend yield is perhaps best considered in relation to those of similar companies.
- AstraZeneca (AZN.LSE): 3.44% (2.48% forward annual dividend yield)
- AbbVie (ABBV.US): 4.70% (4.81% forward annual dividend yield)
- Pfizer (PFE.US): 3.46% (3.51% forward annual dividend yield)
- Edwards Lifesciences Corporation (EW.US): 0.00% (does not pay dividend)
Have Bristol-Myers Squibb's shares ever split?
Bristol-Myers Squibb's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb shares which in turn could have impacted Bristol-Myers Squibb's share price.
Share price volatility
Over the last 12 months, Bristol-Myers Squibb's shares have ranged in value from as little as $55.1871 up to $69.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb's is 0.5879. This would suggest that Bristol-Myers Squibb's shares are less volatile than average (for this exchange).
To put Bristol-Myers Squibb's beta into context you can compare it against those of similar companies.
- AstraZeneca (AZN.LSE): 0.195
- AbbVie (ABBV.US): 0.7909
- Pfizer (PFE.US): 0.679
- Edwards Lifesciences Corporation (EW.US): 1.0753
Shares similar to Bristol-Myers Squibb
Bristol-Myers Squibb in the news
Upcoming Ex-Dividend Dates: September 21-October 4, 2021
European Society for Medical Oncology to hold a virtual meeting
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
Frequently asked questions
More guides on Finder
How to buy IronNet (IRNT) shares in the UK
Ever wondered how to buy shares in IronNet? We explain how and compare a range of providers that can give you access to many brands, including IronNet.
How to buy Rocket Lab USA (RKLB) shares in the UK
Ever wondered how to buy shares in Rocket Lab USA? We explain how and compare a range of providers that can give you access to many brands, including Rocket Lab USA.
How to buy Camber Energy (CEI) shares in the UK
Ever wondered how to buy shares in Camber Energy? We explain how and compare a range of providers that can give you access to many brands, including Camber Energy.
How to buy Aterian (ATER) shares in the UK
Ever wondered how to buy shares in Aterian? We explain how and compare a range of providers that can give you access to many brands, including Aterian.
How to buy eFFECTOR Therapeutics (EFTR) shares in the UK
Ever wondered how to buy shares in eFFECTOR Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including eFFECTOR Therapeutics.
How to buy Santhera Pharmaceuticals Holding (0QN1) shares in the UK
Ever wondered how to buy shares in Santhera Pharmaceuticals Holding AG? We explain how and compare a range of providers that can give you access to many brands, including Santhera Pharmaceuticals Holding AG.
How to buy Basilea Pharmaceutica (0QNA) shares in the UK
Ever wondered how to buy shares in Basilea Pharmaceutica? We explain how and compare a range of providers that can give you access to many brands, including Basilea Pharmaceutica.
How to buy AB Science (0Q77) shares in the UK
Ever wondered how to buy shares in AB Science S.A.? We explain how and compare a range of providers that can give you access to many brands, including AB Science.
How to buy Acacia Pharma Group (0PNT) shares in the UK
Ever wondered how to buy shares in Acacia Pharma Group? We explain how and compare a range of providers that can give you access to many brands, including Acacia Pharma Group.
How to buy Blue Water Acquisition (BLUW) shares in the UK
Ever wondered how to buy shares in Blue Water Acquisition? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Acquisition.
Ask an Expert